Business
Celldex Therapeutics raises USD 345m in stock offering
US-based Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced the closing of an underwritten public offering of common stock on April 6, 2026, raising USD...
Opus Genetics secures USD 155m non-dilutive financing from Oberland Capital Management
Opus Genetics (NASDAQ: IRD), a clinical-stage gene therapy company focused on inherited retinal diseases and headquartered in Research Triangle Park, North...
Neurocrine expands rare disease portfolio via USD 2.9b acquisition of Soleno Therapeutics
Neurocrine Biosciences Expands Rare Disease Portfolio via USD 2.9 Billion Acquisition of Soleno Therapeutics
Stipple Bio closes USD 100m Series A financing for ADC pipeline
Cambridge, Massachusetts-based Stipple Bio, Inc., a private biotechnology company developing epitope-targeted cancer therapies, has closed a USD 100 million...
China's Syneron Bio closes USD 150m Series B for Synova macrocyclic peptide platform
Beijing-based Syneron Bio has closed a USD 150 million Series B financing round to advance its macrocyclic peptide drug discovery platform and accelerate...
Inovio raises USD 17.5m in underwritten public offering
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced a USD 17.5 million underwritten public offering on April 2, 2026, seeking to extend its cash runway as...
Shionogi acquires global RADICAVA rights from Tanabe Pharma for USD 2.5b
Shionogi Acquires Global RADICAVA Rights for USD 2.5 Billion from Tanabe Pharma Corporation
Gilead Sciences extends deadline for Arcellx tender offer
Gilead Sciences Consolidates Full Ownership of Multiple Myeloma CAR T Programme via USD 120.00 Per Share Acquisition of Arcellx
Nuvation Bio takes global control of IDH1 drug safusidenib through Japan market deal with Daiichi Sankyo
Safusidenib, an oral brain-penetrant inhibitor of mutant IDH1, will now advance under a single global rights holder after Nuvation Bio (NYSE: NUVB) amended...
Axsome acquires Takeda's oral PDE10A inhibitor balipodect for neuropsychiatric disorders
Balipodect, an oral selective phosphodiesterase 10A inhibitor originally developed by Takeda Pharmaceutical (NYSE: TAK) as TAK-063, has changed hands in an...
Biocytogen's to support Sihuan Pharma on weight management antibodies
Biocytogen's RenMice platform anchors a strategic partnership with Sihuan Pharmaceutical Holdings Group (HKEX: 0460) that will direct fully human antibody...
Korsana to enter Nasdaq via USD 380m Cyclerion reverse merger
Cyclerion Therapeutics Executes Reverse Merger to Access Public Markets for Korsana Biosciences' THETA™ BBB-Shuttle Platform
Frontier Medicines hands LG Chem license to first-in-class p53 Y220C activator
FMC-220, a covalent small molecule described by Frontier Medicines as a first-in-class activator of the p53 Y220C mutant protein, is the subject of an...
Janux and Bristol Myers Squibb advance tumor-activated T cell engager, triggering USD 35m milestone
A tumor-activated T cell engager generated by Janux Therapeutics (NASDAQ: JANX) using its proprietary TRACTr platform has reached development candidate...
Merck boosts antibody discovery capability through USD 838m partnership with Infinimmune
Infinimmune's Anthrobody® platform has drawn Merck (NYSE: MRK) into a multi-target antibody discovery collaboration structured around human immune...
The AllSci Brief
Systematic R&D and deal news. Daily.